Aldeyra Therapeutics Inc (NASDAQ: ALDX) is 25.45% higher on its value in year-to-date trading and has touched a low of $2.88 and a high of $7.20 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALDX stock was last observed hovering at around $6.30 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $6.26, the stock is -3.00% and 3.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing -0.63% at the moment leaves the stock 22.14% off its SMA200. ALDX registered 117.36% gain for a year compared to 6-month gain of 10.80%. The firm has a 50-day simple moving average (SMA 50) of $6.0334 and a 200-day simple moving average (SMA200) of $5.125475.
The stock witnessed a -5.01% loss in the last 1 month and extending the period to 3 months gives it a 30.69%, and is -6.85% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.94% over the week and 9.32% over the month.
Aldeyra Therapeutics Inc (ALDX) has around 9 employees, a market worth around $373.78M and $0.00M in sales. Distance from 52-week low is 116.98% and -13.06% from its 52-week high. The company has generated returns on investments over the last 12 months (-64.94%).
The EPS is expected to grow by 88.17% this year
159.0 institutions hold shares in Aldeyra Therapeutics Inc (ALDX), with institutional investors hold 64.70% of the company’s shares. The shares outstanding are 59.65M, and float is at 57.98M with Short Float at 6.89%. Institutions hold 63.12% of the Float.
The top institutional shareholder in the company is PERCEPTIVE ADVISORS LLC with over 9.28 million shares valued at $30.7 million. The investor’s holdings represent 15.6121 of the ALDX Shares outstanding. As of 2024-06-30, the second largest holder is KNOLL CAPITAL MANAGEMENT, LLC with 5.48 million shares valued at $18.12 million to account for 9.2158 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 3.74 million shares representing 6.2988 and valued at over $12.39 million, while BLACKROCK INC. holds 6.0961 of the shares totaling 3.62 million with a market value of $11.99 million.
Aldeyra Therapeutics Inc (ALDX) Insider Activity
The most recent transaction is an insider sale by Machatha Stephen, the company’s Chief Development Officer. SEC filings show that Machatha Stephen sold 16,041 shares of the company’s common stock on Aug 12 ’24 at a price of $4.74 per share for a total of $75975.0. Following the sale, the insider now owns 0.24 million shares.
Aldeyra Therapeutics Inc disclosed in a document filed with the SEC on Aug 12 ’24 that Greenberg Bruce sold a total of 10,834 shares of the company’s common stock. The trade occurred on Aug 12 ’24 and was made at $4.74 per share for $51313.0. Following the transaction, the insider now directly holds 0.13 million shares of the ALDX stock.
Still, SEC filings show that on Aug 12 ’24, Greenberg Bruce (Officer) Proposed Sale 10,834 shares at an average price of $5.10 for $55253.0. The insider now directly holds shares of Aldeyra Therapeutics Inc (ALDX).
